

Special Issue

Applications of Mass Spectrometry in Elucidating Human Drug Metabolism: From the Preclinical Phase to Real-World Studies

Message from the Guest Editor

This Special Issue of *Metabolites* aims to highlight novel fundamental and clinical applications of mass spectrometry in characterizing drug metabolism, from preclinical studies to post-marketing clinical studies. We invite contributions across a broad range of topics, including (pharma) cometabolomics, toxicokinetics, pharmacophenotyping, and integrative research focused on mapping and understanding inter-individual variability in pharmacokinetics and drug response. Studies leveraging cutting-edge analytical platforms to investigate metabolic pathways, describe understudied xenobiotic conversion reactions, and improve therapeutic outcomes are particularly welcome.


Guest Editor

Dr. Frank Klont

Groningen Research Institute of Pharmacy, University of Groningen,
9713 AV Groningen, The Netherlands

Deadline for manuscript submissions

closed (1 March 2026)



Metabolites

an Open Access Journal
by MDPI

Impact Factor 3.7
CiteScore 8.1
Indexed in PubMed



mdpi.com/si/238343

Metabolites
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
metabolites@mdpi.com

[mdpi.com/journal/
metabolites](https://mdpi.com/journal/metabolites)





Metabolites

an Open Access Journal
by MDPI

Impact Factor 3.7
CiteScore 8.1
Indexed in PubMed



[mdpi.com/journal/
metabolites](https://mdpi.com/journal/metabolites)



About the Journal

Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

Editor-in-Chief

Dr. Amedeo Lonardo

Internal Medicine, Ospedale Civile di Baggiovara, Azienda Ospedaliero-Universitaria, 41126 Modena, Italy

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Endocrinology, Diabetes and Metabolism)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 3.6 days (median values for papers published in this journal in the second half of 2025).